Nomura Asset Management Co. Ltd. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,900 shares of the medical device company’s stock after buying an additional 1,500 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in DexCom were worth $533,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Advisor Group Inc. raised its stake in shares of DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares during the last quarter. IFP Advisors Inc raised its stake in shares of DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares during the last quarter. Toronto Dominion Bank raised its stake in shares of DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares during the last quarter.

A number of research firms recently weighed in on DXCM. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Piper Jaffray Companies reissued a “buy” rating and set a $87.00 price target on shares of DexCom in a research note on Thursday, September 28th. Northland Securities initiated coverage on shares of DexCom in a report on Tuesday, September 26th. They set an “outperform” rating and a $85.00 price objective for the company. BMO Capital Markets boosted their price objective on shares of DexCom to $74.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, Leerink Swann restated a “buy” rating and set a $57.00 price objective (down previously from $85.00) on shares of DexCom in a report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. DexCom has a consensus rating of “Buy” and an average price target of $71.36.

In other news, CEO Kevin R. Sayer sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $58.85, for a total value of $353,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The disclosure for this sale can be found here. Insiders sold 43,955 shares of company stock valued at $2,583,643 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

DexCom, Inc. (DXCM) opened at $57.04 on Monday. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

WARNING: “Nomura Asset Management Co. Ltd. Acquires 1,500 Shares of DexCom, Inc. (DXCM)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/18/nomura-asset-management-co-ltd-acquires-1500-shares-of-dexcom-inc-dxcm.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related stocks with our FREE daily email newsletter.